Ancora Advisors LLC reported NEUROBIOLOGICAL TECH INC COM (NTII) in 13 quarterly 13F filings from 2023 Q4 through 2023 Q4. The latest visible filing shows NTII at 0.00% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Ancora Advisors LLC's position in NEUROBIOLOGICAL TECH INC COM, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
NTII was reported at 0.00% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
These are the practical questions this page is built to answer before you even open the full history table.
Ancora Advisors LLC reported NTII across 1 quarterly 13F filings, from 2023 Q4 through 2023 Q4.
The largest reported portfolio weight for NTII was 0.00% in 2023 Q4.
The most recent filing on this page is 2023 Q4, when Ancora Advisors LLC reported 2,544,590 shares, equal to 0.00% of portfolio, with an estimated market value of $3.
The chart compares Ancora Advisors LLC's quarterly NTII portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.